Skip to main content

Table 1 Inputs and assumptions for outpatient pneumococcal pneumonia for sample pediatric and adult age groups: 0- < 5 and 50- < 65 years*

From: Attributable healthcare utilization and cost of pneumoniae due to drug-resistant Streptococcus pneumoniae: a cost analysis

     Outcomes (% Cases)
     Concordant treatment Discordant treatment
Sample age groups Antibiotic % cases receiving antibiotic % cases treated discordantly % simple cure % delayed cure % delayed cure and hospitalized % simple cure % delayed cure % delayed cure and hospitalized
Pediatric (0- < 5 yrs) Amoxicillin (High dose) 9% 37% 71% 24% 5% 69% 23% 8%
Amoxicillin (Low dose) 7% 37% 71% 24% 5% 68% 23% 9%
Augmentin 11% 37% 71% 24% 5% 69% 23% 8%
Azithromycin 28% 32% 71% 24% 5% 45% 15% 40%
Oral Cephalosporin (2nd generation) 7% 8% 71% 24% 5% 68% 22% 10%
Oral Cephalosporin (3rd generation) 24% 8% 71% 24% 5% 68% 22% 10%
IM Ceftriaxone 14% 8% 71% 24% 5% 68% 23% 10%
Adult (50- < 65 yrs) Amoxicillin 2% 37% 81% 14% 5% 77% 14% 9%
Augmentin 19% 37% 81% 14% 5% 77% 14% 9%
Azithromycin 15% 29% 81% 14% 5% 51% 9% 40%
Oral Cephalosporin (3rd generation) 9% 6% 81% 14% 5% 77% 14% 10%
IM Ceftriaxone 5% 6% 81% 14% 5% 77% 14% 10%
Fluoroquinolones 56% 1% 81% 14% 5% 51% 9% 40%
  1. *Derived from reference 11. Two age groups are shown as examples of model assumptions and inputs.
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us